实用肝脏病杂志
實用肝髒病雜誌
실용간장병잡지
JOURNAL OF CLINICAL HEPATOLOGY
2013年
6期
517-519
,共3页
慢性丙型肝炎%普通干扰素%利巴韦林%治疗
慢性丙型肝炎%普通榦擾素%利巴韋林%治療
만성병형간염%보통간우소%리파위림%치료
Chronic hepatitis C%Interferon alfa-2b%Vibavirin%Sustained virologic response
目的：观察普通干扰素联合利巴韦林治疗慢性丙型肝炎患者的临床疗效。方法87例慢性丙型肝炎患者被随机分成对照组44例和观察组43例，均应用重组人干扰素α-2b 联合利巴韦林治疗，分别治疗48周和72周，随访24周，观察疗效。结果在44例对照组患者中，HCV 1b型感染者28例（63.6%），2a型感染者8例（18.2%），在观察组43例患者中则分别为29例（67.4%）和6例（14.0%）；对照组获得快速病毒学应答率（RVR）、早期病毒学应答（EVR）、治疗结束时应答（ETR）和持续病毒学应答率（SVR）分别为40.9%、59.1%、68.2%和38.6%，而观察组则分别为39.5%、60.5%、88.4%（P<0.05）和65.1%（P<0.05）；根据血清HCV RNA水平是否≥1×106copies/m1，将两组患者分为高病毒载量组和低病毒载量组，结果两组低病毒载量组患者的ETR和SVR均显著高于高病毒载量组（P<0.05）。结论延长干扰素联合利巴韦林治疗慢性丙型肝炎的疗程有助于提高SVR。
目的：觀察普通榦擾素聯閤利巴韋林治療慢性丙型肝炎患者的臨床療效。方法87例慢性丙型肝炎患者被隨機分成對照組44例和觀察組43例，均應用重組人榦擾素α-2b 聯閤利巴韋林治療，分彆治療48週和72週，隨訪24週，觀察療效。結果在44例對照組患者中，HCV 1b型感染者28例（63.6%），2a型感染者8例（18.2%），在觀察組43例患者中則分彆為29例（67.4%）和6例（14.0%）；對照組穫得快速病毒學應答率（RVR）、早期病毒學應答（EVR）、治療結束時應答（ETR）和持續病毒學應答率（SVR）分彆為40.9%、59.1%、68.2%和38.6%，而觀察組則分彆為39.5%、60.5%、88.4%（P<0.05）和65.1%（P<0.05）；根據血清HCV RNA水平是否≥1×106copies/m1，將兩組患者分為高病毒載量組和低病毒載量組，結果兩組低病毒載量組患者的ETR和SVR均顯著高于高病毒載量組（P<0.05）。結論延長榦擾素聯閤利巴韋林治療慢性丙型肝炎的療程有助于提高SVR。
목적：관찰보통간우소연합리파위림치료만성병형간염환자적림상료효。방법87례만성병형간염환자피수궤분성대조조44례화관찰조43례，균응용중조인간우소α-2b 연합리파위림치료，분별치료48주화72주，수방24주，관찰료효。결과재44례대조조환자중，HCV 1b형감염자28례（63.6%），2a형감염자8례（18.2%），재관찰조43례환자중칙분별위29례（67.4%）화6례（14.0%）；대조조획득쾌속병독학응답솔（RVR）、조기병독학응답（EVR）、치료결속시응답（ETR）화지속병독학응답솔（SVR）분별위40.9%、59.1%、68.2%화38.6%，이관찰조칙분별위39.5%、60.5%、88.4%（P<0.05）화65.1%（P<0.05）；근거혈청HCV RNA수평시부≥1×106copies/m1，장량조환자분위고병독재량조화저병독재량조，결과량조저병독재량조환자적ETR화SVR균현저고우고병독재량조（P<0.05）。결론연장간우소연합리파위림치료만성병형간염적료정유조우제고SVR。
Objective To observe the clinical efficacy of interferon alfa-2b and ribavirin in the treatment of patients with chronic hepatitis C. Methods 87 patients with chronic hepatitis C were randomly divided into two groups,and the patients in both groups were treated with interferon alfa-2b and ribavirin. The regimen lasted for 48 weeks in 44 patients in control and for 72 weeks in 43 patients in the observation group. All the patients were followed-up for 24 weeks after discontinuation of the treatment. Results The HCV genotype 1b and 2a infections were found in 28(63.6%)and 8 patients(18.2%)in the control group,while they were in 29(67.4%)and 6 patients(14.0%)in the observation groups;The rapid virologic response(RVR),early virologic response(EVR), virologic response at the end of treatment(ETR)and sustained virologic response(SVR)in control group were 40.9%, 59.1%,68.2% and 38.6%,respectively,while they were 39.5%,60.5%,88.4%(P<0.05)and 65.1%(P<0.05),respec-tively in the observation group;We divided the patients in both groups into with high and low serum virologic loads as their serum HCV RNA≥1í106copies/m1,the ETR and SVR in patients with low serum virologic load in both groups were higher than those in patients with high serum viral loads (P<0.05). Conclusion Prolonged course of interferon-α and ribavirin treatment in patients with chronic hepatitis C might improve the efficacy and get higher SVR.
